These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19836845)

  • 1. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
    Crawford Y; Ferrara N
    Trends Pharmacol Sci; 2009 Dec; 30(12):624-30. PubMed ID: 19836845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathways mediating VEGF-independent tumor angiogenesis.
    Ferrara N
    Cytokine Growth Factor Rev; 2010 Feb; 21(1):21-6. PubMed ID: 20005148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis.
    Ferrara N
    Curr Opin Hematol; 2010 May; 17(3):219-24. PubMed ID: 20308892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
    Greenberg JI; Cheresh DA
    Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy for cancer: an update.
    Shojaei F; Ferrara N
    Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
    Ellis LM; Hicklin DJ
    Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor.
    Ferrara N
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):789-91. PubMed ID: 19164810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
    Shojaei F
    Cancer Lett; 2012 Jul; 320(2):130-7. PubMed ID: 22425960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why do tumors become resistant to antiangiogenesis drugs?
    Schmidt C
    J Natl Cancer Inst; 2009 Nov; 101(22):1530-2. PubMed ID: 19880813
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to vascular endothelial growth factor blockade.
    Abdullah SE; Perez-Soler R
    Cancer; 2012 Jul; 118(14):3455-67. PubMed ID: 22086782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.